Must be able to take oral medication without crushing, dissolving or chewing tablets
Able to swallow oral medication as an intact dosage form
Able to take oral medication without crushing, dissolving or chewing tablets
Patients must be able to consume oral medication in the form of tablets or solution
Must be able to take oral medication without crushing, dissolving or chewing capsules
Participant is able to take an oral medication.
Participant is able to take oral medication.
Able to swallow oral medication.
Patients must be able to consume oral medication
Not able to take oral medication
Patient must be able to take oral/enteral medication
Unable to receive oral medication
For oral cohorts: subject is able to swallow the oral capsule medication.
Able to swallow oral medication
Able to take oral medication without crushing, dissolving or chewing tablets
Must be able to swallow ribociclib and oral aromatase inhibitor, such as letrozole
Able to swallow oral medication as an intact dosage form
Able to swallow oral medication
Able to take oral medication
Subjects must be able to consume oral medication
Be able to take oral medication
Unable to swallow medication
Patients must be able to consume oral medication
Unable to swallow medication or suspected malabsorption
Must be able to take oral medication
Patient should be able to take oral medication (dasatinib must be swallowed whole)
The patient is unable to swallow capsules and/or has a surgical or anatomical condition that precludes swallowing and absorbing oral medication on an ongoing basis (for oral therapy only).
Subjects who are able to take oral medication.
Unable to swallow oral medication.
Patients must be able to swallow oral medication
Able to swallow and absorb the medication
Able to swallow oral medication
Subjects must be able to consume oral medication
Able to swallow or have medication administered through a gastrostomy tube (G-tube) and absorb the medication
Patient is unable to swallow or keep down oral medication
Able to take oral medication and has no history of gastric surgery or pathology
Able to swallow or have medication administered through a gastrostomy (G)-tube and absorb the medication
Patients must be able to swallow medication by oral route
The patient must be able to swallow oral medication.
Able to swallow oral medication
All study participants must be able to swallow oral medication
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome
Patients who are unable to swallow oral medication are not eligible
Are able to swallow oral medication.
Participants must be able to take oral medication
Patients must be able to swallow oral medication
The patient is unable to swallow capsules and/or has a surgical or anatomical condition that precludes swallowing and absorbing oral medication on an ongoing basis (for oral therapy only)
Patients must be able to take oral medication without crushing, dissolving or chewing tablets
Is unable to swallow oral medication
Able to take oral medication
Subjects must be able to consume oral medication
Patient is not able to swallow oral medication
Able to swallow and absorb the medication
Patient is not able to swallow oral medication
Patient should be able to take oral medication (dasatinib must be swallowed whole)
Patients must be able to take oral medication without crushing, dissolving, or chewing tablets
Patient is not able to swallow oral medication
Unable to swallow medication
Unable to swallow medication; suspected malabsorption
Able to swallow medication
Subject must be able to swallow medication
Must be able to ingest, absorb and tolerate oral medication
Able to take oral medication
Patient must be able to tolerate oral medication
Must be able to take oral medication without crushing, dissolving or chewing tablets
Patients must be able to take oral medication.
Patients with epilepsy requiring permanent oral medication
Able to tolerate oral medication
Able to swallow medication
Must be able to take oral medication without crushing, dissolving or chewing tablets
Be able to swallow medication
Patients are not eligible if they are unwilling or unable to comply with the protocol
Patients who are unable to swallow oral medication or are unwilling to comply with the administration requirements are not eligible
Patients who are unwilling or unable to comply with the protocol are not eligible
Must be able to swallow pills
Patients must be able to swallow pills
Patients must be able to swallow pills and must not have malabsorption problems or ongoing nausea and vomiting that would affect oral treatment
Subjects who are unable to swallow pills
Patient must be able to swallow pills whole
Ability to swallow pills or capsules
Subject is able to swallow pills.
Subject is unable to swallow pills
The ability to swallow pills and otherwise follow the protocol
Participant must be able to swallow pills
Ability to swallow pills/capsules
Ability to take pills by mouth
For Combination Therapy cohort only: Able to swallow pills.
Patients must be able to swallow whole pills
Must be able to swallow pills
Men unable to swallow pills
Patients who are unable to swallow pills
Patient must be able to swallow pills
Ability to take pills by mouth
Participants must be able to swallow oral pills
Must be able to swallow pills or capsules
Patient is not able to swallow pills
Any condition that impairs patient‘s ability to swallow whole pills
Patient must be able to swallow pills
Patients must be able to swallow pills
PHASE II: Patients must be able to swallow pills
Patients who are unable to swallow pills or who have undergone surgery that prohibits the absorption of pills in the stomach
Ability to swallow pills
Patients unable to swallow pills.
Patients who are unable to swallow pills/capsules are ineligible
Able to swallow pills
Ability to swallow pills or capsules
Must be able to swallow pills.
Able to swallow pills
Patients unable or unwilling to swallow pills
Patients must have the ability to swallow pills
Patient must be able to swallow pills
Any condition that impairs patient‘s ability to swallow whole pills
Must be able to swallow pills
Ability to swallow pills
Patients who are unable to swallow pills
Patients must be able to swallow pills
Patients who are unable to swallow pills
Patients must be able to swallow pills
Patients who are unable to swallow pills are excluded
Patient must be able to swallow pills
PHASE II: Patient must be able to swallow pills
Patient must be able to swallow pills
Any condition that impairs the patient’s ability to swallow whole pills
Patient must be able to swallow pills
Patient must be able to swallow pills and have no significant impairment in gastrointestinal absorption including history of gastric bypass surgery
Unable to swallow pills
Subject cannot reliably swallow pills
Participant must be able to swallow pills
Participant must be able to swallow pills
Able to swallow pills
Ability to take pills by mouth
Patients who cannot swallow pills
Able to swallow pills
Willingness to swallow pills and no medical condition that would interfere with this
Any condition that impairs patient‘s ability to swallow whole pills
Must be able to swallow whole pills
Any condition that impairs patient‘s ability to swallow whole pills; patients with feeding tubes, intractable nausea or vomiting, or a malabsorption syndrome are not eligible
Any condition that impairs patient's ability to swallow whole pills
Patient must be able to swallow pills
Ability to swallow pills and keep medication record
The ability to swallow pills
Inability to take oral medications on a continuous basis; patients who are to take pazopanib, sorafenib, or sunitinib and are unable to swallow pills whole are ineligible (the pills cannot be crushed or broken)
Patients who are unable to swallow pills
Patients who are unable to swallow pills are not eligible
Unable to swallow pills
Patients must be able to safely swallow pills.
Patients must be able to swallow pills
Patient must be able to swallow pills
Any condition that impairs patient’s ability to swallow pills will make patient ineligible
Patient must be able to swallow pills
Patients must be able to swallow whole pills
Able to swallow pills
Participants must be able to swallow pills to participate in the study
Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption of pills; patients must be able to swallow pills
Any condition that severely impairs patient’s ability to swallow whole pills
Any condition that impairs patient‘s ability to swallow whole pills
Any condition that impairs patient‘s ability to swallow whole pills
Any condition that impairs patient‘s ability to swallow whole pills
Ability to take pills by mouth
Patients must be able to swallow pills
Patients must be able to swallow pills and have no significant impairment in gastrointestinal absorption
Able to swallow pills
Participant must be able to swallow pills (psychology staff will be available to assist with pill swallowing training if needed)
Participants who are unable to swallow pills
Patients must be able to swallow pills
Participant must be able to swallow pills
Patients must be able to swallow pills
Able to swallow pills
Ability to swallow pills
Inability to swallow oral medications
Inability to swallow oral medications
Inability to take oral medications
Inability to swallow medications
Inability to tolerate oral medications.
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Inability to take oral medications
Patients must not have significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medications.
Inability to swallow or absorb drug
Inability to swallow oral medications.
Inability to swallow medications
Inability to swallow oral medications
Inability or unwillingness to swallow oral medications
Significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications
Inability to swallow or tolerate oral medication.
Inability to swallow oral medications
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications
inability to take oral medication
inability to take oral medication;
Inability to tolerate oral medication
Inability or unwilling to swallow study drug
Inability to swallow medication
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
Inability to swallow medications
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications
Any gastrointestinal tract disease or other medical condition resulting in the inability to take oral medications
Inability to swallow intact tablets or inability to take pembrolizumab or cabozantinib
Inability to swallow medication
Inability to take oral medications on a continuous basis
Inability to take medications by mouth
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Inability to swallow oral medication
Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications
Inability to take oral medication
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements or GI procedure that could interfere with the oral absorption or tolerance of treatment
Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Inability to take oral medications
Inability to swallow pills or any significant gastrointestinal diseases, which would preclude adequate absorption of oral medications.
PART B: Patients with inability to take oral medications, or, in the investigator’s opinion, gastrointestinal conditions or abnormalities likely to influence the absorption of oral medications
Inability to swallow oral medications or any malabsorption condition
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
Inability to swallow or absorb drug
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal condition that could interfere with the oral absorption or tolerance of treatment.
Significant malabsorption syndrome or inability to tolerate oral medications
Inability to swallow oral medications
Inability to take oral medication
Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications
Clinical conditions affecting the intake and use of oral medications (e.g., inability to swallow, chronic diarrhea, and intestinal obstruction)
Inability to tolerate oral medications.
Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
Has inability to swallow oral medications or presence of a gastrointestinal disorder (e.g. malabsorption) deemed to jeopardize intestinal absorption of MK-8628
Inability to swallow oral medications or any medical conditions that may affect intestinal absorption of the study agent or inability to comply with oral medication
Inability to take oral medications, due to impaired swallowing ability or poor absorption capacity
Inability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatment
Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications
Inability to swallow oral medications
Inability to take oral medications
Inability to swallow food or any condition of the upper GI tract that precludes administration of oral medications.
Inability to swallow oral medication or condition that could interfere with oral absorption or tolerance of treatment
Inability to swallow oral medications
Inability to swallow or absorb drug
Inability to swallow oral medications (unless patients use a feeding tube in which case they are eligible)
Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications
Inability to cooperate with NIPPV
Inability to swallow study medication
Inability to swallow oral medications
Inability to take medications by mouth
Have a known history of inability to absorb an oral agent
Participants with known inability to adequately absorb oral medication
Have a known history of inability to absorb an oral agent
Ability to swallow entrectinib intact
Subjects must be able to swallow whole capsule.
Ability to swallow the study drug as a whole tablet
Participant is able to swallow a tablet whole
Ability to swallow the study drugs
Ability to swallow the study drug as a whole tablet.
Patient must be able to swallow capsule or tablet
Able to swallow study drugs whole as a tablet/capsule.
Must be able to swallow ribociclib (LEE-011) tablet/capsule
Patient must be able to swallow tablet or have existing gastrostomy feeding tube to enable administration of tablet
Able to swallow the study drugs whole
Able to swallow the study drugs whole as a tablet
Able to swallow study drugs whole as a tablet/capsule
Patients who are not able to swallow the lenalidomide capsule as a whole are excluded from this study; (capsule cannot be opened, chewed, or crushed)
Capacity to swallow
Willingness and ability to swallow study drugs
Patients must be able to swallow whole capsule
Patient must be able to swallow capsule or tablet
Patients must have the ability to swallow the study drug whole as a tablet or capsule
Ability to swallow liquids
Able to swallow the study drugs whole.
Ability to swallow the study drugs whole.
Patients who are not able to swallow the lenalidomide capsule as a whole are excluded from this study (capsule cannot be opened, chewed, or crushed)
Unable to swallow a whole tablet or capsule.
Ability to swallow study drug whole as a capsule
Ability to swallow the study drugs
Able to swallow thin liquids
Subjects that are unable to swallow a tablet/pill for any reason
Subjects that are unable to swallow a tablet/pill
Patient is able to swallow a capsule
Able to swallow the study drug(s) whole as a tablet
Able to swallow the study drug whole as a tablet
Able to swallow the study drug and comply with study requirements
Able to swallow the study drug whole as a tablet.
Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements.
Able to swallow study drug
Able to swallow sunitinib and comply with study requirements
Able to swallow study drug and comply with study requirements
Able to swallow study drug and comply with study requirements
Able to swallow study drug and comply with study requirements
Able to swallow the study drug and comply with study requirements
Patients should be able to swallow enzalutamide and comply with study requirements
Patients must be able to swallow the drug
Vasectomy or surgical castration ? 6 months prior to Screening. 13. Subjects able to swallow study medication 14. Subjects able to comply with study requirements
Subject must be able to swallow study drug and comply with study requirements.
Able to swallow the study drug as a whole tablet
Able to swallow the study drug whole as a tablet
Subject is able to swallow the study drug and comply with study requirements.
Able to swallow the study drug whole as a tablet
Able to swallow the study drug whole as a tablet
Able to swallow the study drug and comply with study requirements
Able to swallow the study drug whole as a tablet
Able to swallow the study drug whole as a tablet
Able to swallow the study drug and comply with study requirements
Able to swallow the study drug as prescribed and comply with study requirements
Able to swallow the study drug, have no known intolerance to the study drug or excipients, and comply with study requirements.
Able to swallow the study drug whole as a tablet
Able to swallow enzalutamide and comply with study requirements
Able to swallow the study drug (no contraindication to oral agents).
Able to swallow the study drug (no contra indication to oral agents).
Able to swallow the study drug whole as a tablet
Able to swallow supplements
Patients must be able to tolerate oral medications by mouth, and not have a gastrointestinal illness that would preclude absorption of olaparib
Inability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of BGB-290, which is an oral agent.
Patients must be able to tolerate oral medications and not have gastrointestinal processes that would preclude absorption of olaparib
Any known gastrointestinal disorders which would preclude oral administration of 5-azacitidine
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
COHORT 3: ENDOMETRIAL CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation
COHORT 3: ENDOMETRIAL CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
Patients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of AZD8186
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Able to tolerate oral medications and no GI illnesses that would preclude absorption of olaparib
UROTHELIAL CARCINOMA EXPANSION COHORT: Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of olaparib
Ability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted.
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agents
PHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C): \r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agents
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agents
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients must be able to swallow oral medications without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib which are an oral agent
Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
Patient is able to tolerate oral medications and does not have gastrointestinal illnesses that would preclude absorption of either olaparib or BKM120 or BYL719
Able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of AZD2014, AZD5363, or olaparib (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease)
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of GSK1120212 and GSK2141795
Any known gastrointestinal disorders which would preclude oral administration of 5-azacitidine
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation
Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of AZD1775 (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease); Note: patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN)
Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of BMN 673 (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease)
Subject must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after alisertib administration
Willing to fast for 6 hours before and 2 hours after Oradoxel administration
Ability to swallow oral medications and maintain an empty stomach state for 2 hours prior to the MLN0128 dose and for 1 hour following administration
Ability to swallow oral medications and maintain an empty stomach state for two hours prior to the TAK-228 dose and for one hour following administration
Must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after capsule(s) administration
Subject must be able to take oral medication and to maintain a fast, as is required for 2 hours before and 1 hour after alisertib (MLN8237) administration
According to current guidelines, patients must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration; these guidelines may change pending results from an ongoing food effects study
Patients must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration
Inability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowel
Ability to swallow oral medications and maintain an empty stomach state for 2 hours prior to the MLN0128 dose and for 1 hour following administration
Inability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowel
Patient must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration
Able and willing to swallow and absorb orally administered medications and maintain a fast as required before and after MLN8237 administration
Subject must be able to take oral medication and to maintain a fast as required before and after MLN8237 administration
Subjects must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration
Subjects must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration.
According to current guidelines, patients must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration; these guidelines may change pending results from an ongoing food effects study
Inability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowel
